Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
February 26 2021 - 2:00AM
Tiziana Life Sciences (NASDAQ: TLSA; LSE:
TILS), a biotechnology company focused on innovative therapeutics
for oncology, inflammation, and infectious diseases, today
announced that an interview with its CEO, Dr Kunwar Shailubhai,
will air on The RedChip Money Report on Bloomberg Television on
Saturday, February 27, 2021 at 7 p.m. local time across the United
States and on the Bloomberg Network in Europe on Sunday, February
28, 2021 at 6 p.m. local time. The RedChip Money Report airs on
Bloomberg Television U.S. on Saturdays at 7 p.m. local time in 73M
homes and on the Bloomberg Network in Europe in 100M homes at 6
p.m. local time on Sundays.
In the exclusive interview, Dr Shailubhai
discusses topline data from Tiziana’s COVID-19 trial, its multiple
Phase 2 trial launches expected in 2021, and the potential
application of Foralumab in a wide range of autoimmune and
inflammatory diseases.
“The RedChip Money Report" delivers insightful
commentary on small-cap investing, interviews with Wall Street
analysts, financial book reviews, as well as featured interviews
with executives of public companies.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
Milciclib, the Company is also developing Foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis
(NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc (TLSA)
Gabriele Cerrone, Chairman and
founder
+44 (0)20 7495 2379
U.S. Investor Relations Contact:
RedChip Companies, Inc.Dave
Gentry407-491-4498dave@redchip.com
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Apr 2023 to Apr 2024